{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:52:33Z","timestamp":1793508753029,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpurol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Urology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jpurol.2023.06.007","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T18:46:06Z","timestamp":1686854766000},"page":"535.e1-535.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost analysis for mirabegron use in the treatment of children with neurogenic bladder"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0142-7589","authenticated-orcid":false,"given":"Rena","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Balthazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sherlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jpurol.2023.06.007_bib1","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/nau.24657","article-title":"Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: an open-label, phase 3, dose-titration study","volume":"40","author":"Baka-Ostrowska","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2023.06.007_bib2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.urology.2016.05.067","article-title":"Preoperative risk factors predicting complication rates of augmentation cystoplasty using the modified clavien classification system in pediatric population","volume":"97","author":"Telli","year":"2016","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.jpurol.2023.06.007_bib3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/nau.23857","article-title":"Long-term functional outcomes of augmentation cystoplasty in adult spina bifida patients: a single-center experience in a multidisciplinary team","volume":"38","author":"Perrouin-Verbe","year":"2019","journal-title":"Neurourol Urodyn"},{"issue":"9","key":"10.1016\/j.jpurol.2023.06.007_bib4","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/j.1464-410X.2011.10650.x","article-title":"The past, present and future of augmentation cystoplasty","volume":"109","author":"Biers","year":"2012","journal-title":"BJU Int"},{"issue":"3\u20134","key":"10.1016\/j.jpurol.2023.06.007_bib5","first-page":"249","article-title":"Effect of bladder augmentation on VP shunt failure rates in spina bifida","volume":"10","author":"Gonzalez","year":"2017","journal-title":"J Pediatr Rehabil Med"},{"issue":"4","key":"10.1016\/j.jpurol.2023.06.007_bib6","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.juro.2013.04.075","article-title":"National trends in augmentation cystoplasty in the 2000s and factors associated with patient outcomes","volume":"190","author":"Schlomer","year":"2013","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.jpurol.2023.06.007_bib7","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3171\/2020.9.PEDS20313","article-title":"Shunt infection and malfunction in patients with myelomeningocele","volume":"27","author":"White","year":"2021","journal-title":"J Neurosurg Pediatr"},{"issue":"3","key":"10.1016\/j.jpurol.2023.06.007_bib8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/JU.0000000000000299","article-title":"Risk of reaugmentation after enterocystoplasty using a reconfigured bowel segment in patients with spina bifida: a Bi-institutional cohort study","volume":"202","author":"VanderBrink","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2023.06.007_bib9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s12913-015-1040-8","article-title":"Predicting inpatient hospital payments in the United States: a retrospective analysis","volume":"15","author":"Smith","year":"2015","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.jpurol.2023.06.007_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00345-010-0618-3","article-title":"Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity","volume":"29","author":"Padmanabhan","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.jpurol.2023.06.007_bib11","article-title":"Cost comparison of intra-detrusor injection of botulinum toxin versus augmentation cystoplasty for refractory neurogenic detrusor overactivity in children","author":"Kim","year":"2022","journal-title":"J Pediatr Urol"},{"issue":"4","key":"10.1016\/j.jpurol.2023.06.007_bib12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.clinthera.2013.02.020","article-title":"Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States","volume":"35","author":"Carlson","year":"2013","journal-title":"Clin Therapeut"},{"issue":"5","key":"10.1016\/j.jpurol.2023.06.007_bib13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jpurol.2020.07.020","article-title":"Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction","volume":"16","author":"Sager","year":"2020","journal-title":"J Pediatr Urol"},{"key":"10.1016\/j.jpurol.2023.06.007_bib14","article-title":"Beta-3 adrenoceptor agonist for the treatment of bladder dysfunction in children: a systematic review and meta-analysis","author":"Kim","year":"2021","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.jpurol.2023.06.007_bib15","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00345-018-2576-0","article-title":"Efficacy and safety of mirabegron, a \u03b23-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study","volume":"37","author":"Park","year":"2019","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.jpurol.2023.06.007_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4111\/icu.20200380","article-title":"Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: a preliminary study","volume":"62","author":"Kim","year":"2021","journal-title":"Investig Clin Urol"},{"issue":"1","key":"10.1016\/j.jpurol.2023.06.007_bib17","doi-asserted-by":"crossref","first-page":"31 e1","DOI":"10.1016\/j.jpurol.2019.10.009","article-title":"The pharmacokinetics, safety, and tolerability\u00a0of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation","volume":"16","author":"Rittig","year":"2020","journal-title":"J Pediatr Urol"},{"issue":"1","key":"10.1016\/j.jpurol.2023.06.007_bib18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/nau.24588","article-title":"OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children","volume":"40","author":"Austin","year":"2021","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"10.1016\/j.jpurol.2023.06.007_fur1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1442-2042.2006.01240.x","article-title":"Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability","volume":"13","author":"Kilic","year":"2006","journal-title":"Int J Urol"},{"issue":"1","key":"10.1016\/j.jpurol.2023.06.007_fur2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.ju.0000147813.28822.d2","article-title":"Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction","volume":"173","author":"Franco","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2023.06.007_fur3","series-title":"Upjohn Detrol","year":"2008"},{"issue":"6","key":"10.1016\/j.jpurol.2023.06.007_fur4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jpurol.2008.05.003","article-title":"Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity","volume":"4","author":"Reddy","year":"2008","journal-title":"J Pediatr Urol"},{"issue":"2","key":"10.1016\/j.jpurol.2023.06.007_fur5","doi-asserted-by":"crossref","first-page":"180.e1","DOI":"10.1016\/j.jpurol.2019.12.012","article-title":"Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies","volume":"16","author":"Franco","year":"2020","journal-title":"J Pediatr Urol"},{"issue":"5","key":"10.1016\/j.jpurol.2023.06.007_fur6","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1097\/01.ju.0000085667.05190.ad","article-title":"Trospium chloride for the treatment of detrusor instability in children","volume":"170","author":"Lopez Pereira","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2023.06.007_fur7","series-title":"Medical officer\u2019s review NDA","first-page":"21","year":"2004"},{"issue":"12","key":"10.1016\/j.jpurol.2023.06.007_fur8","doi-asserted-by":"crossref","first-page":"828","DOI":"10.4111\/kju.2014.55.12.828","article-title":"Efficacy, tolerability, and safety of oxybutynin chloride in pediatric neurogenic bladder with spinal dysraphism: a retrospective, multicenter, observational study","volume":"55","author":"Lee","year":"2014","journal-title":"Korean J Urol"},{"issue":"1","key":"10.1016\/j.jpurol.2023.06.007_fur9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0090-4295(97)00489-5","article-title":"Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia","volume":"51","author":"Goessl","year":"1998","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.jpurol.2023.06.007_fur10","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1046\/j.1464-410X.2003.04085.x","article-title":"The use of tolterodine in children after oxybutynin failure","volume":"91","author":"Bolduc","year":"2003","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.jpurol.2023.06.007_fur11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000102915","article-title":"Long-term efficacy of tolterodine and patient compliance in pediatric patients with neurogenic detrusor overactivity","volume":"79","author":"Christoph","year":"2007","journal-title":"Urol Int"},{"issue":"2","key":"10.1016\/j.jpurol.2023.06.007_fur12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eururo.2003.10.009","article-title":"Retrospective analysis of efficacy and tolerability of tolterodine in children with overactive bladder","volume":"45","author":"Raes","year":"2004","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.jpurol.2023.06.007_fur13","doi-asserted-by":"crossref","DOI":"10.3834\/uij.1944-5784.2011.02.17","article-title":"Efficacy and safety of trospium chloride use in children with idiopathic and neurogenic detrusor overactivity: an overview of available data","volume":"4","author":"B\u00fcrst","year":"2011","journal-title":"UroToday Int J"},{"key":"10.1016\/j.jpurol.2023.06.007_fur14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.urology.2018.02.033","article-title":"Intradetrusor injections of botulinum toxin type A in children with spina bifida: a multicenter study","volume":"116","author":"Hascoet","year":"2018","journal-title":"Urology"},{"issue":"8","key":"10.1016\/j.jpurol.2023.06.007_fur15","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00192-018-3653-z","article-title":"A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder","volume":"29","author":"Shepherd","year":"2018","journal-title":"Int Urogynecol J"},{"issue":"6","key":"10.1016\/j.jpurol.2023.06.007_fur16","doi-asserted-by":"crossref","first-page":"533.e1","DOI":"10.1016\/j.jpurol.2018.05.028","article-title":"Thirty-day hospital readmissions after augmentation cystoplasty: a Nationwide readmissions database analysis","volume":"14","author":"Maldonado","year":"2018","journal-title":"J Pediatr Urol"}],"container-title":["Journal of Pediatric Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477513123002358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477513123002358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:54:46Z","timestamp":1761486886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477513123002358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1477513123002358"],"URL":"https:\/\/doi.org\/10.1016\/j.jpurol.2023.06.007","relation":{},"ISSN":["1477-5131"],"issn-type":[{"value":"1477-5131","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost analysis for mirabegron use in the treatment of children with neurogenic bladder","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpurol.2023.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}